CRISPR Therapeutics (NASDAQ:CRSP) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

CRISPR Therapeutics (NASDAQ:CRSP) issued its quarterly earnings results on Monday. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09), FiscalAI reports. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $12.67 million during the quarter, compared to analysts’ expectations of $14.75 million. The firm’s revenue was up 1311.1% on a year-over-year basis.

CRISPR Therapeutics Stock Down 2.8%

Shares of CRSP opened at $49.99 on Tuesday. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $64.74. The company has a market capitalization of $4.83 billion, a PE ratio of -10.50 and a beta of 1.76. The stock has a fifty day simple moving average of $54.00 and a two-hundred day simple moving average of $52.89. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. William Blair upgraded CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. HC Wainwright reissued a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.75.

Insider Activity

In related news, Director Ali Behbahani sold 13,679 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the sale, the director owned 16,637 shares of the company’s stock, valued at approximately $949,806.33. This represents a 45.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Simeon George sold 14,514 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total transaction of $720,329.82. Following the sale, the director owned 15,486 shares of the company’s stock, valued at approximately $768,570.18. The trade was a 48.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 93,558 shares of company stock worth $4,881,663. 5.20% of the stock is owned by insiders.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY sales accelerated: Third-quarter CASGEVY revenue reached $99 million, up 30% sequentially and nearly sixfold from the year-earlier period. The therapy also received expanded pediatric approvals in the U.K., United Arab Emirates and Bahrain, improving its commercial opportunity. CRISPR Therapeutics Third-Quarter 2026 Results
• Positive Sentiment: Pipeline progress: The FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also expects to present CTX310 and zugo-cel clinical data at upcoming medical conferences and completed enrollment in a Phase 2 CTX611 trial. These developments could provide future catalysts. CRISPR Therapeutics Business Update
• Neutral Sentiment: Brokerage view remains a focus: Recent coverage reviews what analysts and brokerages think about CRSP, but the available report details do not identify a major change in consensus ratings or price targets. Brokerage Views on CRISPR Therapeutics
• Neutral Sentiment: Manufacturing leadership added: CRISPR appointed Siva Sakhamuri, Ph.D., as chief technical officer. His experience in biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticles may support commercialization, but the appointment is unlikely to materially affect near-term earnings. CRISPR Therapeutics CTO Appointment
• Negative Sentiment: Quarterly results missed expectations: CRISPR reported a third-quarter loss of $1.15 per share versus the roughly $1.04 analyst consensus, while revenue of $12.67 million fell short of estimates near $14.75 million. The company remains deeply unprofitable and continues to depend heavily on its cash reserves to fund its costly development pipeline. CRISPR Therapeutics Earnings Flash

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.